Endothelin receptor antagonists for use in treating or preventing muscle fibrosis
AssigneesAssociation Institut De Myologie, Sorbonne Universite, Inserm (Institut National De La Sante Et De La Recherche Medicale)
InventorsMONA BENSALAH, ANNE BIGOT, LAURA MURAINE, ELISA NEGRONI, CAPUCINE TROLLET
Life of this patent
Estimating the term…
Abstract
The present invention concerns endothelin receptor antagonists for use in the treatment or the prevention of muscle fibrosis.
Claims20
1-13. (canceled)
A method of treating or preventing muscle fibrosis comprising administering an endothelin receptor antagonist or a pharmaceutical composition comprising an endothelin receptor antagonist to a patient having a muscle fibrosis.
A kit-of-parts comprising or consisting of:
- at least one endothelin receptor antagonist, and
- a means for carrying out a gene therapy or cellular therapy or pharmacological therapy for use in the treatment of a myopathy or a muscular dystrophy,
- for simultaneous, separate or sequential use in the treatment or the prevention of muscle fibrosis in patients suffering from a myopathy or a muscular dystrophy.
An in vitro method for diagnosing muscle fibrosis in a human subject suspected of suffering from muscle fibrosis, said method comprising:
- determining the circulating endothelin level in a biological sample obtained from said human subject;
- and
- comparing said circulating endothelin level with a reference level to correlate said circulating endothelin level to the presence or absence of muscle fibrosis in said human subject.
A method for evaluating the effectiveness of an anti-fibrotic treatment, said method comprising:
- determining the circulating endothelin level in a biological sample obtained from a human subject under a treatment of muscle fibrosis;
- and
- comparing said circulating endothelin level with an initial level to evaluate the effectiveness of said treatment of muscle fibrosis.
Dependencies are inferred from the claim text.